PARSLOW JAMES F 4

What Happened

• James F. Parslow, Interim CEO and CFO of Xenetic Biosciences (XBIO), was granted 100,000 restricted shares on April 21, 2026. The shares were issued at $0.00 (no cash paid) as an award/grant (Form 4 code A).

Key Details

• Transaction date: 2026-04-21; Form filed: 2026-04-23 (filed timely).
• Grant size and price: 100,000 shares, $0.00 per share (total cash paid $0).
• Vesting (footnote F1): 7,000 shares vest immediately on grant date; the remaining 93,000 shares vest in three equal installments of 31,000 shares on each of the 1st, 2nd and 3rd anniversaries of April 21, 2026.
• Shares owned after transaction: Not disclosed in the information provided on this filing.
• Transaction type: Award/Grant (code A) — a compensation event, not a market purchase or sale.

Context

• Restricted stock grants are compensation and typically vest over time; they do not by themselves indicate a buy/sell signal from the insider. This filing reports the grant and the vesting schedule; any future sales or exercises would appear in later filings.